SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSI Technology ($GSIT) is trending due to news highlighting their Compute-In-Memory APU achieving GPU-class AI performance with significantly lower energy costs, sparking community interest in its potential to compete with industry giants like NVDA. Discussions revolve around the APU's performance and energy efficiency, with some viewing GSIT as an overlooked player in the AI and drone sectors due to its exposure to high-speed memory solutions and defense contracts.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is trending as community members discuss the company's potential shift towards rare earth production and a possible deal with a major global steel producer. Some investors are optimistic about the company's future growth in the rare earth market, while others remain skeptical, pointing to debt concerns. Overall, the stock's potential direction is being debated amid discussions of sector tailwinds.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group is trending as community members discuss the potential impact of the FDA accepting the resubmission of its Biologics License Application for RP1, a melanoma treatment. The news has sparked debate about future prospects, regulatory flexibility, and potential market moves. Discussions also include Wedbush's updated rating and price target.

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded on August 5, 1988 and is headquartered in Queensbury, NY.

Delcath Systems Inc

Delcath Systems ($DCTH) is trending due to pre-market volatility and upcoming earnings, with the community closely watching for explanations regarding Q3/Q4 revenue weakness. Bullish investors are focused on the long-term potential of the CHOPIN trial data, which could significantly expand the platform's applicability, while others are concerned about revenue guidance and profitability. Discussions also involve high gross margins, potential dilution, and speculation about a possible buyout.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending following Q3 revenue announcements and increased FY2025 guidance, with much of the community discussion focused on the potential impact of DefenCath sales and the Melinta acquisition. Some investors are expressing frustration with the stock's performance despite positive news, while others remain optimistic about the company's long-term prospects and potential catalysts, such as a possible deal with DaVita and developments related to TLPH.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

Celcuity is trending due to positive Phase 3 breast cancer trial data, sparking discussions about its potential as a new standard of care and a possible buyout target. Community members are analyzing the company's financials and debating the likelihood of a near-term offering, with some anticipating significant upside and others expressing caution about a potential pullback. Overall, there is excitement about the company's prospects within the biotech sector.

Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA.

RAPT Therapeutics Inc

RAPT Therapeutics is trending following the announcement of positive topline data from its Phase 2 trial of RPT904 in Chronic Spontaneous Urticaria, leading to discussions about potential price targets and the strength of the biotech momentum. However, some community members are expressing concerns about potential offerings and drops, while others remain optimistic about the company's future and potential breakouts. The stock is also being mentioned in connection with other trending stocks and potential squeeze opportunities.

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.

Corbus Pharmaceuticals Holdings Inc

CRBP is trending amid discussions of market manipulation and a significant drop from pre-market highs, despite recent analyst upgrades and price targets. The community is actively debating the impact of upcoming catalysts and data releases, particularly around CRB-701, while also noting the high institutional ownership and short interest. Overall, conversation is centered on the potential for a rebound following an overreaction to news in the broader sector, with some seeing it as a buying opportunity.

FGI Industries Ltd. engages in the supply of kitchen and bath products. Its products fall under the following categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The Sanitaryware category offers bath products such as toilets, sinks, pedestals and toilet seats. The Bath Furniture category deals with wood and wood-substitute furniture for bathrooms, including vanities, mirrors, laundry and medicine cabinets, and other storage systems. The Shower Systems category includes a range of shower-related products such as shower walls, shower doors and shower basins. The Others category includes shower door and shower systems products, custom kitchen cabinetry, and other accessory items. The company was founded on May 26, 2021 and is headquartered in East Hanover, NJ.

FGI Industries Ltd

FGI is trending due to significant intraday price movement, sparking community discussion around potential short squeezes and speculative momentum. The stock's surge, despite a lack of fundamental news, has drawn comparisons to other low float tickers experiencing similar patterns. Traders are actively watching for continued volatility and potential profit-taking opportunities.

Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.

Cogent Biosciences Inc

Cogent Biosciences ($COGT) is trending as the community discusses its potential as the next buyout target, drawing comparisons to the $BPMC-$SNY deal. Positive analyst ratings, strong buy recommendations, and key upcoming data readouts for bezuclastinib are also fueling investor interest. Some traders are noting technical breakouts and increased volume, while others are wary of potential volatility and dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
